Preclinical Characterization of Mobocertinib Highlights the Putative Therapeutic Window of This Novel EGFR Inhibitor to EGFR Exon 20 Insertion Mutations
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Mar 01, 2021
- Source ID
- 10.1016/j.jtocrr.2020.100105
Entities
People
- Daniel B Costa
- Ikei S. Kobayashi
- Pedro E.n.s. Vasconcelos
- Susumu S Kobayashi
Organizations
- National Cancer Institute
- United States Department of Defense